|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Cohen HT and McGoven FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nagase H and Woessner JF: Matrix
metalloproteinases. J Biol Chem. 274:21491–21494. 1999. View Article : Google Scholar
|
|
4
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Björklund M and Koivunen E:
Gelatinase-mediated migration and invasion of cancer cell. Biochim
Biophys Acta. 1755:37–69. 2005.PubMed/NCBI
|
|
6
|
Sobin LH and Wittekind CH: International
Union Against Cancer (UICC) TNM classification of malignant tumors.
6th edition. Wiley-Liss; New York, NY: pp. 193–195. 2002
|
|
7
|
Bradford MM: A rapid and sensitive method
for quantitation of microgram quantities of protein utilizing the
principle of protein-dye binding. Anal Biochem. 72:248–254. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Di Carlo A, Terracciano D, Mariano A and
Macchia V: Urinary gelatinase activities (matrix metalloproteinase
2 and 9) in human bladder tumors. Oncol Rep. 15:1321–1326.
2006.PubMed/NCBI
|
|
9
|
Di Carlo A, Terracciano D, Mariano A and
Macchia V: Matrix metalloproteinase-2 and matrix
metalloproteinase-9 type IV collagenases in serum of patients with
pleural effusions. Int J Oncol. 26:1363–1368. 2005.PubMed/NCBI
|
|
10
|
Triebel S, Bläser J, Reinke H and
Tschesche H: A 25 kDa α2-microglobulin-related protein
is a component of the 125 kDa form of human gelatinase. FEBS Lett.
314:386–388. 1992.
|
|
11
|
Yan L, Borregaard N, Kjeldsen L and Moses
MA: The high molecular weight urinary matrix metalloproteinase
(MMP) activity is a complex of gelatinase B/MMP and neutrophil
gelatinase-associated lipocalin (NGAL). J Biol Chem.
276:37258–37265. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roy R, Louis GL, Loughlin KR, Wiederschain
D, Kilroy SM, Lamb CC, Zurakowski D and Moses MA: Tumor-specific
urinary matrix metalloproteinase fingerprinting: identification of
high molecular weight urinary matrix metalloproteinase species.
Clin Cancer Res. 14:6610–6617. 2008. View Article : Google Scholar
|
|
13
|
Goldberg GI, Strongin A, Collier IE,
Genrich LT and Marmer BL: Interaction of 92-kDa type IV collagenase
with the tissue inhibitor of metalloproteinases prevents
dimerization, complex formation with interstitial collagenase, and
activation of proenzyme with stromelysin. J Biol Chem.
267:4583–4591. 1992.
|
|
14
|
Russo P: Localized renal cell carcinoma.
Curr Treat Options Oncol. 2:447–455. 2001. View Article : Google Scholar
|
|
15
|
Kashyap MK, Kumar A, Emelianenko N,
Kaahyap A, Kaushik R, Huang R, Khullar M, Sharma SK, Singh SK,
Bhargave AK and Upadhyava SK: Biochemical and molecular markers in
renal cell carcinoma: an update and future prospects. Biomarkers.
10:258–294. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Struckmann K, Mertz K, Steu S, Storz M,
Staller P, Krek W, Schraml P and Moch H: pVHL co-ordinately
regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell
renal cell carcinoma. J Pathol. 214:464–471. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kallakury BV, Karikehalli S, Haholu A,
Sheehan CE, Azumi N and Ross JS: Increased expression of matrix
metalloproteinases 2 and 9 and tissue inhibitors of
metalloproteinases 1 and 2 correlate with poor prognostic variables
in renal cell carcinoma. Clin Cancer Res. 7:3113–3119.
2001.PubMed/NCBI
|
|
18
|
Abdel-Wahed MM, Asaad NY and Aleskandarany
M: Expression of matrix metalloproteinase-2 in renal cell
carcinoma. J Egypt Nat Canc Inst. 16:168–177. 2004.PubMed/NCBI
|
|
19
|
Kugler A, Hemmerlein B, Thelen P,
Kallerhoff M, Radzun HJ and Ringert RH: Expression of
metalloproteinase 2 and 9 and their inhibitors in renal cell
carcinoma. J Urol. 160:1914–1918. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kamiya N, Kishimoto T, Suzuki H, Sekita N,
Nagai Y, Oosumi N, Kito H, Tochigi N, Shinbo M, Nemori R, et al:
increased in situ gelatinolytic activity in renal cell tumor
tissues correlates with tumor size, grade and vessel invasion. Int
J Cancer. 106:480–485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lein M, Jung K, Laube C, Hübner T,
Winkelmann B, Stephan C, Hauptmann S, Rudolph B, Schnorr D and
Loening SA: Matrix-metalloproteinases and their inhibitors in
plasma and tumor tissue of patients with renal cell carcinoma. Int
J Cancer. 85:801–804. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cannon GM and Getzenberg RH: urinary
matrix metalloproteinases activity is not significantly altered in
patients with renal cell carcinoma. Urology. 67:848–850. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sherief MH, Low SS, Miura M, Kudo N,
Novick A and Weimbs T: Matrix metalloproteinase activity in urine
of patients with renal cell carcinoma leads to degradation of
extracellular matrix proteins: possible use as a screening assay. J
Urol. 169:1530–1534. 2003. View Article : Google Scholar
|
